



Figure S1




**Figure S1.** Down-regulation of Onc-p53 induces BIM and sensitizes SCLC to venetoclax in H211 cells. (A) Onc-p53 was downregulated by shRNA (shp53) in H211 cells. The levels of BCL-2 family proteins compared to scrambled shRNA control (shC) were determined by Western blots with the indicated antibodies. (B) The levels of *Bim* mRNA in H211 shp53 and scrambled RNA control cells were determined by qRT-PCR. (C) H211 shp53 and scrambled RNA control cells were treated with 1  $\mu$ M venetoclax. Total cell extracts were prepared at the indicated time points and were subjected to Western blots with the indicated antibodies. \*\*p<0.01. Error bars equal SD.

Figure S2



**Figure S2.** Down-regulation of BIM mitigates cell death induced by venetoclax and ganetespib in H211 cells. H211 shBIM and scrambled RNA control cells were treated with 1  $\mu$ M venetoclax and/or 50 nM ganetespib. Total cell extracts were prepared at the indicated time points and were subjected to Western blots with the indicated antibodies.

Figure S3




**Figure S3.** Co-immunoprecipitation with normal IgG indicates that anti-BCL-2 and anti-BIM antibodies are specific. H1048 cells were treated with 1  $\mu$ M venetoclax and/or 50 nM ganetespib for 8 hours. Total cell lysates were subjected to immunoprecipitation with (A) normal mouse IgG and anti-BCL-2 antibodies, (B) normal rabbit IgG and anti-BIM antibodies. Western blot analyses were carried out on precipitated samples with the indicated antibodies. Input demonstrated the integrity of each cell lysate.


# Original Western Blots

In 300 dpi


Fig 1A




BCL-2 (25 kD)




MCL-1 (40 kD)




BCL-XL (30 kD)



GAPDH (37 kD)




p53 (53 kD)




BIM<sub>EL</sub> (25 kD)


Fig 1C



p53 (53 kD)




GAPDH (37 kD)




Cleaved Caspase 3 (19 kD)

Fig 2A




p53 (53 kD)




GAPDH (37 kD) and BIM<sub>EL</sub> (25 kD)

Fig 2D




Cleaved Caspase 3 (19 kD)



GAPDH (37 kD)




Fig 4B




p53 (53 kD), GAPDH (37 kD), BIM<sub>EL</sub> (25 kD),  
Cleaved Caspase 3 (19 kD)


Fig 5B




BIM<sub>EL</sub> (25 kD)



GAPDH (37 kD)




GAPDH (37 kD)




Cleaved Caspase 3 (19 kD)


Fig 6A



Cleaved PARP (89 kD)




BCL-2 (25 kD)




GAPDH (37 kD) and BIM<sub>EL</sub> (25 kD)


Fig 6B




GAPDH (37 kD)



Cleaved PARP (89 kD)




BIM<sub>EL</sub> (25 kD)




BCL-2 (25 kD)

Fig 6C




IgG heavy chain (~50 kD) and GAPDH (37 kD)




BAX (20 kD)


Fig S1A




BIM<sub>EL</sub> (25 kD)




BCL-2 (25 kD)



p53 (53 kD) and GAPDH (37 kD)




BCL-XL (30 kD)




MCL-1 (40 kD)


Fig S1C



p53 (53 kD)




Cleaved Caspase 3 (19 kD)




GAPDH (37 kD)


Fig S2



BIM<sub>EL</sub> (25 kD)




GAPDH (37 kD)




Cleaved Caspase 3 (19 kD)



Fig S3



BIM<sub>EL</sub> (25 kD)



BCL-2 (25 kD)